Scientists Create 3D Heart Cell-On-Chip Platform

BioTecNika | August 27, 2019

Researchers in the US and Singapore have developed an organ-on-chip platform which uses bio-electrical sensors to measure the electrical properties of heart cells in 3D. The research study published in the latest edition of Science Advances showed that 3D, self-rolling biosensor arrays were made to coil up over heart cell spheroid tissues to form an organ-on-e-chip, or say 3D heart cell-on-chip platform that enables the scientists to study how these cells communicate with each other in a multicellular system such as the heart. The 3D heart cell-on-chip platform can help develop and assess the efficacy of various drugs for disease treatment. This may allow researchers to screen for drugs as well as the toxins directly on a human-like tissue, instead of testing those on animal tissue. Formerly, scientists used cells and cultures on 2D surfaces, such as culture dishes. But now, they have developed a way to shrink-wrap sensors around heart cells to extract electrophysiological information from heart tissue. The scientists from Carnegie Mellon University and Nanyang Technological Universitypinned an array of sensors made of either graphene sensors or metallic electrodes to the chip’s surface then etched off a bottom layer of germanium.

Spotlight

Nathan Ledeboer, Medical Director of Microbiology & Molecular Diagnostics, Medical College of Wisconsin. An example of how rapid diagnostics can postively impact patient care. "We were in fact so successful [with AMS processes] that our providers were waiting for that result to come out before they even made a decision how to manage the patient"

Spotlight

Nathan Ledeboer, Medical Director of Microbiology & Molecular Diagnostics, Medical College of Wisconsin. An example of how rapid diagnostics can postively impact patient care. "We were in fact so successful [with AMS processes] that our providers were waiting for that result to come out before they even made a decision how to manage the patient"

Related News

CELL AND GENE THERAPY

Neurophth and AAVnerGene Announces Strategic AAV Capsids Partnership for Next-Generation Ophthalmic Gene Therapy

Neurophth | January 19, 2021

Neurophth Therapeutics, Inc., a subsidiary of Wuhan Neurophth Biotechnology Ltd. gene therapy organization, and AAVnerGene Inc., a practicing AAV innovation organization, reports a strategic partnership to provide Neurophth with overall rights to commonly choose adeno-associated virus (AAV) capsids for the next generation ophthalmic gene therapy. AAVnerGene's Tissue-specific, Highly-transductive and Expressive New AAVs (ATHENA) screening stage can productively choose the best AAV vector for every cell type in a high-throughput (HTP) way. Significant difficulties in AAV-based gene therapy are the transduction productivity, conceivable resistance to the capsid and complex assembling measures. The capacity to distinguish appropriate cutting edge AAV vectors that could beat the limits of before generation AAV vectors is basic to a patient for accomplishing adequate helpful articulation of the moved gene in the most minimal portion dose regular strategy, for example, intravitreal (IVT) injection with reasonable cost. "AAVnerGene's proprietary technology may create capsid libraries derived from artificial intelligence machine learning, DNA shuffling or directed evolution allowing a significant increase in AAV genetic payload capacity, production, and transduction with the ability to penetrate through the inner limiting membrane of the retina, thus potentially enhance the overall transduction efficiency of capsid library-derived AAV vectors," said Alvin Luk, Ph.D., M.B.A., Chief Executive Officer of Neurophth. "Importantly, if proven successful, the administration of the selected AAVnerGene capsid variant(s) in gene therapy may enable repeated dosing AAVs in both adults and pediatric patients, potentially improving the clinical efficacy at a lower vector dose with better penetration of the barriers in eyes using a safer and less invasive procedure such as intravitreal injection which lower the risk of immune response to the capsid."

Read More

CELL AND GENE THERAPY

AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for the Research and Development of CAR-T Cell Therapeutics

AbbVie | February 11, 2021

AbbVie and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome altering biotechnology organization, reported today that they have gone into a cooperation and permit arrangement for the innovative work of fanciful antigen receptor (CAR)- T cell therapeutics. Albeit allogeneic, "off-the-shelf" CAR-T cell therapies have indicated early guarantee in some malignancy patients, the requirement for beating the dismissal of allogeneic CAR-T cells by the host immune system stays a vital test to their more extensive turn of events. Utilizing Caribou's CRISPR genome editing platform to engineer CAR-T cells to withstand have resistant assault would empower the advancement of the next-generation of "off-the-shelf" cellular therapies to benefit a broader patient population. "We are excited to partner with AbbVie on the development of new CAR-T cell therapies. This collaboration validates Caribou's differentiated next-generation CRISPR genome editing technologies that provide best-in-class efficiency and specificity," said Rachel Haurwitz, Ph.D., President and Chief Executive Officer of Caribou. "We believe AbbVie is an ideal partner for Caribou as we expand upon the number of targets and diseases addressable by our technologies. Genome-edited CAR-T cell therapies hold tremendous potential for patients, and this partnership accelerates our ability to address significant unmet medical need." About AbbVie AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. About Caribou Biosciences, Inc. Caribou is a leading clinical-stage CRISPR genome editing biotechnology company founded by pioneers of CRISPR biology. Outside of this collaboration, Caribou is advancing an internal pipeline of allogeneic cell therapies for oncology. CB-010, Caribou's lead allogeneic CAR-T cell program, targets CD19 and is being evaluated in a Phase 1 clinical trial for patients with relapsed/refractory B cell non-Hodgkin lymphoma. CB-011, Caribou's second allogeneic CAR-T cell therapy, targets BCMA for multiple myeloma, and CB-012, Caribou's third allogeneic CAR-T cell therapy, targets CD371 for acute myeloid leukemia. CB-011 and CB-012 are in preclinical development. Additionally, Caribou is developing iPSC-derived allogeneic natural killer (NK) cell therapies for solid tumors. Through its next-generation CRISPR genome editing technologies, Caribou is implementing multiple strategies to boost CAR-T and NK cell persistence to overcome cell exhaustion and to prevent rapid immune-mediated clearance. These sophisticated edits drive the durability of clinical benefit of these off-the-shelf medicines.

Read More

ProteoNic Announces Licensing of Technology for Boosting Therapeutic Protein Production to Immunomedics

ProteoNic | October 20, 2020

ProteoNic BV, a leading provider of technology and services in the field of production of biologics, today announced it has licensed its premium 2G UNic™ technology for boosting therapeutic protein production to Immunomedics, Inc. (NASDAQ: IMMU), a biopharmaceutical company developing immuno-therapeutics for the treatment of cancer and other diseases. Under the agreement, Immunomedics gains commercial rights for application of ProteoNic's technology platform to the development of specified proprietary products from mammalian cells. Financial details of the agreement were not disclosed. ProteoNic's protein expression technology improves production levels across a range of host cells, selection systems and protein targets. It increases transcription and translation rates via a combination of novel genetic elements, which together exert a powerful positive effect on recombinant protein production levels without impacting product quality or cell line stability attributes. 2G UNic™ can be readily combined with other protein expression-enhancing technologies to improve their performance.

Read More